drugset / Trial / NCT04259944
Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
Phase 2
Unknown
140 enrolled
IFOM ETS - The AIRC Institute of Molecular Oncology
Guardant Health, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
PEGASUS is a prospective multi-centric study designed to prove the feasibility of using liquid biopsy to guide the post-surgical and post-adjuvant clinical management in 140 microsatellite stable Stage-III and T4N0 Stage-II colon cancer patients.
Timeline
- Start
- 2020-06-16
- Primary completion
- 2024-07-15
- Completion
- 2024-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Capecitabine | Small molecule | 1250 mg/m2 | Oral |
| Subject | FOLFIRI | Other / unclassified | 400 mg/m2 | Intravenous |
| Subject | IRI | Unknown | 180 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 400 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |